FDA inspections of tissue banks remain a work in progress, and no clear path yet exists for procuring human tissues for biomedicine or drug development. Emily Waltz investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Waltz, E. Nat. Med. 12, 487–488 (2006).
Human Tissue Task Force. 2007 Report (Department of Health & Human Services, Public Health Service, Food and Drug Administration, Bethesda, Maryland, USA, 2007). <http://www.fda.gov/cber/tissue/httf07report.htm>.
Waltz, E. Nat. Med. 13, 391 (2007).
National Institutes of Health Revitalization Act of 1993 <http://www.hhs.gov/ohrp/humansubjects/guidance/publiclaw103-43.htm>.
Anonymous. Taken without consent. The Guardian 31 January (2001) <http://society.guardian.co.uk/alderhey/comment/0,431159,00.html>.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waltz, E. Tracking down tissues. Nat Biotechnol 25, 1204–1206 (2007). https://doi.org/10.1038/nbt1107-1204
Issue Date:
DOI: https://doi.org/10.1038/nbt1107-1204
This article is cited by
-
Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study
Journal of Cancer Education (2020)
-
Predictors of biospecimen donation in the Black Women’s Health Study
Cancer Causes & Control (2016)
-
Disparities in knowledge and willingness to donate research biospecimens: a mixed-methods study in an underserved urban community
Journal of Community Genetics (2014)
